WAM
NYMX

Warberg Asset Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Warberg Asset Management’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50,500
Closed -$22K – 328
2022
Q2 		$22K Buy
50,500
+25,925
+105% +$23.8K ﹤0.01% 180
2022
Q1 		$31K Buy
+24,575
New +$37.9K ﹤0.01% 173

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSA
Leonteq Securities AG Zurich, Switzerland $2.7B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Warberg Asset Management's NYMX Position: Q3 2022 in Review

Warberg Asset Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2022, closing a stake of 50,500 shares — an estimated $22K sold.

Warberg Asset Management first reported a position in NYMX in Q1 2022 and held it in 2 quarters. The position peaked at $31K in Q1 2022. 34 funds tracked by Wall St. Rank hold NYMX as of Q3 2022.

  • Warberg Asset Management reported no remaining Nymox Pharmaceutical Corp position as of Q3 2022 after selling out during the quarter.
  • Warberg Asset Management sold 50,500 Nymox Pharmaceutical Corp shares in Q3 2022, an estimated $22K.
  • Warberg Asset Management first reported a position in Nymox Pharmaceutical Corp in Q1 2022 and held it in 2 quarters.
  • Warberg Asset Management's Nymox Pharmaceutical Corp position peaked at $31K in Q1 2022.
  • 34 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2022.

Based on Warberg Asset Management's 13F filing for Q3 2022, filed 7 Nov 2022.